JP2007523206A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007523206A5 JP2007523206A5 JP2007500150A JP2007500150A JP2007523206A5 JP 2007523206 A5 JP2007523206 A5 JP 2007523206A5 JP 2007500150 A JP2007500150 A JP 2007500150A JP 2007500150 A JP2007500150 A JP 2007500150A JP 2007523206 A5 JP2007523206 A5 JP 2007523206A5
- Authority
- JP
- Japan
- Prior art keywords
- depression
- disorder
- features
- sleep
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000024732 dysthymic disease Diseases 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000020595 eating behavior Effects 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 208000025319 neurotic depression Diseases 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0404104A GB0404104D0 (en) | 2004-02-24 | 2004-02-24 | Compounds |
| GB0425069A GB0425069D0 (en) | 2004-11-12 | 2004-11-12 | Compounds |
| PCT/EP2005/001938 WO2005080342A1 (en) | 2004-02-24 | 2005-02-22 | Pyridine derivatives and their use as cb2 receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007523206A JP2007523206A (ja) | 2007-08-16 |
| JP2007523206A5 true JP2007523206A5 (enExample) | 2008-03-21 |
Family
ID=34889143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007500150A Withdrawn JP2007523206A (ja) | 2004-02-24 | 2005-02-22 | Ｃｂ２受容体モジュレーターとしてのピリジン誘導体およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080280868A1 (enExample) |
| EP (1) | EP1718613B1 (enExample) |
| JP (1) | JP2007523206A (enExample) |
| AT (1) | ATE407119T1 (enExample) |
| DE (1) | DE602005009500D1 (enExample) |
| ES (1) | ES2313304T3 (enExample) |
| WO (1) | WO2005080342A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
| TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| WO2008063625A2 (en) * | 2006-11-20 | 2008-05-29 | Adolor Corporation | Pyridine compounds and methods of their use |
| CA2719538C (en) * | 2008-04-07 | 2014-03-18 | Amgen Inc. | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors |
| RU2011143740A (ru) | 2009-03-30 | 2013-05-10 | Астеллас Фарма Инк. | Соединение пиримидина |
| US9012651B2 (en) * | 2011-03-24 | 2015-04-21 | Abbvie Inc. | TRPV3 modulators |
| US8865723B2 (en) | 2012-10-25 | 2014-10-21 | Tetra Discovery Partners Llc | Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury |
| WO2015095442A1 (en) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Piperidinyloxy lactone orexin receptor antagonists |
| CN112638430B (zh) | 2018-06-27 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 放射性标记的大麻素受体2配体 |
| EP3814328A1 (en) | 2018-06-27 | 2021-05-05 | F. Hoffmann-La Roche AG | Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
| CR20200643A (es) * | 2018-06-27 | 2021-05-11 | Eth Zuerich | Nuev0s compuestos de piridina y pirazina com0 inhibidores del receptor connabinoide 2 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5112820A (en) * | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
| FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
-
2005
- 2005-02-22 JP JP2007500150A patent/JP2007523206A/ja not_active Withdrawn
- 2005-02-22 AT AT05715507T patent/ATE407119T1/de not_active IP Right Cessation
- 2005-02-22 ES ES05715507T patent/ES2313304T3/es not_active Expired - Lifetime
- 2005-02-22 US US10/597,524 patent/US20080280868A1/en not_active Abandoned
- 2005-02-22 WO PCT/EP2005/001938 patent/WO2005080342A1/en not_active Ceased
- 2005-02-22 EP EP05715507A patent/EP1718613B1/en not_active Expired - Lifetime
- 2005-02-22 DE DE602005009500T patent/DE602005009500D1/de not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007520539A5 (enExample) | ||
| JP2008501758A5 (enExample) | ||
| JP2007523206A5 (enExample) | ||
| JP2003511434A (ja) | モノアミン再取込み阻害剤として有用な新規ビアリールエーテル誘導体 | |
| RU2008139481A (ru) | Новые 1,4-диаза-бицикло[3.2.2]нонил-оксадиазолильные производные и их медицинское применение | |
| RU2010119560A (ru) | Замещенные n-фенилбипирролидинкарбоксамиды и их терапевтическое применение | |
| KR20190139874A (ko) | 카파 오피오이드 수용체 길항제 및 그와 관련된 제품 및 방법 | |
| BR122017023795B8 (pt) | método para preparação de composição farmacêutica | |
| RU2007139255A (ru) | Новые оксадиазольные производные и их медицинское применение | |
| WO2007099423A1 (en) | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists | |
| RU2015143466A (ru) | Нейроактивные стероиды и способы их применения | |
| JP2013540794A (ja) | 疼痛、精神病性障害、認知障害、またはアルツハイマー病の治療のためのアルファ‐７ニコチン性受容体修飾薬 | |
| RU2009136330A (ru) | Тетрагидроизохинолиновые соединения в качестве модуляторов гистаминового н3 рецептора | |
| JP2020502092A5 (enExample) | ||
| MX2010009643A (es) | Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a). | |
| CN106061964A (zh) | 能够刺激神经发生的n‑苯基‑内酰胺衍生物及其在神经性病症的治疗中的用途 | |
| JP2007523207A5 (enExample) | ||
| EP2614824B1 (en) | Triazole derivative for use in the treatment of neuropathic pain and fibromyalgia | |
| NO20092688L (no) | Forbindelser med en kombinasjon av cannabinoid-CB1 antagonisme og acetylcholinesteraseinhibering | |
| JP2008543782A (ja) | ５−ｈｔ１ａ受容体のピペラジン−ピペリジンアンタゴニストおよびアゴニスト | |
| JP2010514682A5 (enExample) | ||
| JP2007520537A5 (enExample) | ||
| JP2006502157A5 (enExample) | ||
| JP2009518337A5 (enExample) | ||
| MX2010008239A (es) | 2-aminoquinolinas. |